Association of leptin and ghrelin changes with weight response after dapagliflozin treatment in type 2 diabetes: a prospective interventional study
Cardiovascular Prevention and Pharmacotherapy · 2026-07-31 · 8 (3) · 58-66
DOI: 10.36011/cpp.2026.8.e9 ↗At a glance
Journal article in Cardiovascular Prevention and Pharmacotherapy, published on 2026-07-31. Written by Jun Hwa Hong. Cited 1 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Korean Diabetes Association.
Topics: Diabetes mellitus
Abstract (original language)
Background
To compare changes in serum leptin and ghrelin according to weight response in patients with type 2 diabetes treated with dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i).
Methods
In this prospective single-arm interventional study, 97 patients received dapagliflozin 10 mg daily. Serum leptin and ghrelin were measured before treatment and after 3 months of dapagliflozin treatment. Participants were divided into two groups according to their 3-month glycated hemoglobin (HbA1c) level: the target group, with HbA1c ≤7.0% (n=45), and the above-target group, with HbA1c >7.0% (n=52). Additional analyses were performed according to body weight change: the weight-loss group (n=60) and the weight-gain group (n=37). Changes in serum leptin and ghrelin were compared between groups.
Results
After 3 months of treatment, the mean HbA1c level was 6.7%±0.1% in the target group and 7.3%±0.2% in the above-target group. Serum leptin and ghrelin did not differ significantly between these groups. In the weight-loss group, serum leptin decreased significantly from 7.54±3.51 to 6.60±2.40 ng/mL (P
Funding
- Korean Diabetes Association
Cite
APA
Hong, J. H. (2026). Association of leptin and ghrelin changes with weight response after dapagliflozin treatment in type 2 diabetes: a prospective interventional study. Cardiovascular Prevention and Pharmacotherapy, 8(3), 58-66. https://doi.org/10.36011/cpp.2026.8.e9
Vancouver
Hong JH. Association of leptin and ghrelin changes with weight response after dapagliflozin treatment in type 2 diabetes: a prospective interventional study. Cardiovascular Prevention and Pharmacotherapy. 2026;8(3):58-66. doi:10.36011/cpp.2026.8.e9
BibTeX
@article{Hong2026,
author = {Hong, Jun Hwa},
title = {Association of leptin and ghrelin changes with weight response after dapagliflozin treatment in type 2 diabetes: a prospective interventional study},
journal = {Cardiovascular Prevention and Pharmacotherapy},
year = {2026},
volume = {8},
number = {3},
pages = {58--66},
doi = {10.36011/cpp.2026.8.e9}
}
EUVIMED